- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Orexigen Therapeutics Inc
Add to PortfolioOREX:US
3.4700 USD 0.1400 4.20%As of 17:20:00 ET on 05/29/2012.
Snapshot for Orexigen Therapeutics Inc (OREX)
| Open: | 3.3100 | Day's Range: | 3.3100 - 3.4800 | Volume: | 483,247 | Bid: | 3.4600 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 3.3300 | 52wk Range: | 1.2200 - 5.1400 | 1-Yr Rtn: | +21.33% | Ask: | 3.4700 |
Key Statistics for OREX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (USD) (ttm) | -0.5100 |
| Est. EPS (USD) (12/2012) | -0.8350 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 235.19 |
| Shares Outstanding (M) | 67.78 |
| Enterprise Value (M USD) (ttm) | 96.61 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 2.5862 |
| Price/Sale (ttm) | 52.4914 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/08/2012 |
More OREX Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for OREX
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for OREX
Orexigen Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of the central nervous system, or CNS, disorders with an initial focus on obesity.
| Eckard WeberChairman/Founder | Michael NarachiPresident/CEO |
| Mark D BoothChief Commercial Officer | Heather D TurnerSenior VP/Secretary/Gen Cnsl |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page